TAR003
Undisclosed solid tumors
Pre-clinicalActive
Key Facts
About TargImmune Therapeutics
TargImmune Therapeutics is a private, pre-clinical stage biotech developing a first-in-class targeted nucleic acid delivery platform known as Targeted Apoptosis and Immune Modulators (TAIMs). The platform utilizes synthetic nanoparticles to deliver interchangeable nucleic acid payloads, such as double-stranded RNA (dsRNA), directly to tumors, inducing both cancer cell death and immune modulation. The lead program, TAR001, targets EGFR-overexpressing cancers and is on track for an IND/CTA filing in the first half of 2024, with the platform holding potential for application beyond oncology.
View full company profileTherapeutic Areas
Other Undisclosed solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Macrophage-Targeting Agonist Antibody | Bolt Biotherapeutics | Phase 1 |
| IMA204 | Immatics Biotechnologies | Phase 1 |
| TAR002 | TargImmune Therapeutics | Pre-clinical |
| Proprietary TCR-NK Platform | Zelluna Immunotherapy | Preclinical |
| ERAS-113 | Erasca | Discovery |
| Multiple Programs | Aktis Oncology | Discovery |
| BAT5506 | Compugen | Preclinical |
| Precision DACs | Prelude Therapeutics | Discovery |
| V2ACT Immunotherapy | Genelux | Phase 1 |
| ATOR-4066 | Alligator Bioscience AB | Discovery/Preclinical |
| ACR-6840 | Acrivon Therapeutics | Preclinical |
| ADC Program | Lantern Pharma | Discovery/Preclinical |